PhD Supervisor, Chief Physician, Professor, Vice President of the Western District of the First Affiliated Hospital of USTC and Anhui Provincial Cancer Hospital. Renowned Jianghuai Doctor, leader of the 115 Industry Team, Director of the Oncology Teaching and Research Office, Executive Director of the Clinical Research Institute of Drugs, and Deputy Director of the Anhui Provincial Cancer Quality Control Center. Board member of the Chinese Society of Clinical Oncology (CSCO).
Vice Chair of the CSCO Translational Medicine Committee, Vice Chair of the CSCO Cardiac Safety Committee, Standing Committee Member of the CSCO Lung Cancer Expert Committee, Standing Committee Member of the CSCO Breast Cancer Expert Committee, National Committee Member of the Chinese Medical Association Oncology Branch, Standing Committee Member of the Chinese Medical Association Multidisciplinary Oncology Committee, Member of the Breast Cancer Expert Committee of the National Cancer Center, President of the Anhui Clinical Oncology Society, Vice President of the Anhui Anti-Cancer Association, and Member of the CSCO Immunology Expert Committee. He is also the Chair-elect of the Anhui Medical Association Breast Disease Branch and Chair of the Anhui Anti-Cancer Association Breast Cancer Committee. He has received the First Prize of Anhui Science and Technology Progress Award and published over 50 SCI papers as the first or corresponding author, including in journals such as Nature Cell Biology, ACS Nano, JTO, and CCR.
Education and Work Experience
1982.09–1987.07: Bachelor’s degree from Wannan Medical College
1987–1990: Resident Physician in Oncology, Second Affiliated Hospital of Wannan Medical College
1990–1994: Resident Physician in Oncology, First Affiliated Hospital of Anhui Medical University
1994–2000: Attending Physician in Oncology, First Affiliated Hospital of Anhui Medical University
1997–2000: Master’s degree in Public Health, Anhui Medical University
2000–2007: Associate Chief Physician in Oncology, First Affiliated Hospital of Anhui Medical University
2003–2007: PhD in Clinical Pharmacology, Anhui Medical University
2007–2008: Visiting Scholar at Harvard Medical School, BWH/Dana-Farber
2007–2016: Chief Physician in Oncology, First Affiliated Hospital of Anhui Medical University
2016–Present: Vice President, Western District of the First Affiliated Hospital of USTC
Academic Achievements and Impact
Received the First Prize of Anhui Science and Technology Progress Award, recognized as a Jianghuai Doctor, and leader of the 115 Industry Team.
Published over 50 SCI papers in journals such as Nature Cell Biology, ACS Nano, JTO, and CCR, with a total citation count of approximately 1100.
Current Research Projects (Main Responsible Person Only)
Project Title: Development of an International Standard Demonstrative New Drug Clinical Evaluation Platform with a Focus on Antitumor Drugs, Subproject: AI-Assisted Evaluation of Pulmonary Lesions in Antitumor Drug Clinical Trials Source: National Major Science and Technology Project Funding: 2.566 million RMB Duration: 2020-01 to 2021-12
Project Title: Molecular Mechanism of Stress Granules Leading to Tumor Cell Drug Resistance Source: New Medicine of USTC Joint Fund, Key Direction Project Funding: 8 million RMB Duration: 2019-07 to 2022-06
Project Title: Role and Mechanism of has_circ_001090 in Promoting EGFR-TKI Resistance in Non-Small Cell Lung Cancer Source: Anhui Provincial Natural Science Foundation, General Project Funding: 2 million RMB Duration: 2019-07 to 2022-06
Project Title: Efficacy Evaluation of Standard Dose Neoadjuvant Chemotherapy in Chinese Breast Cancer Patients and the Predictive Value of NGS, ctDNA, and Multi-Parameter MRI Source: Anhui Provincial Science and Technology Project Funding: 6 million RMB Duration: 2021-01 to 2023-12
Project Title: Changes in Immune Cell Subpopulations and Their Relationship with Efficacy, Prognosis, and Resistance in the Treatment of Advanced Triple-Negative Breast Cancer with Sintilimab and Albumin-Bound Paclitaxel Funding: 2 million RMB Duration: 2020-01 to 2023-12
Main Research Directions (Admissions Major) and Content
Clinical Medicine
1. Oncology
- Mechanisms of resistance in lung and breast cancer
- Anti-tumor effects of immune cells and strategy optimization
Representative Papers (Last Five Years)
1. Xing L#, Pan Y#, Shi Y, Shu Y, Feng J, Li W, Cao L, Wang L, Gu W, Song Y, Xing P, Liu Y, Gao W, Cui J, Hu N, Li R, Bao H, Shao Y, Yu J*. Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M-positive Non-Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study. Clinical Cancer Research. 2020 Dec 1;26(23):6168-6175.
2. Huang Y#, Wang H, Hao Y, Lin H, Dong M, Ye J, Song L, Wang Y, Li Q, Shan B, Jiang Y, Li H, Shao Z, Kroemer G, Zhang H, Bai L, Jin T, Wang C, Ma Y, Cai Y, Ding C, Liu S*, Pan Y*, Jiang W*, Zhou R*. Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity[J]. Nature Cell Biology.2020 Jun;22(6):716-727.
3. Shan B, Broza YY, Li W, Wang Y, Wu S, Liu Z, Wang J, Gui S, Wang L, Zhang Z, Liu W, Zhou S, Jin W, Zhang Q, Hu D, Lin L, Zhang Q, Li W, Wang J, Liu H, Pan Y*, Haick H*. Multiplexed Nanomaterial-Based Sensor Array for Detection of COVID-19 in Exhaled Breath[J]. ACS Nano. 2020 Sep 22;14(9):12125-12132.
4. Zhang Y#, Xu B#, Shi J#, Li J, Lu X, Xu L, Yang H, Hamad N, Wang C, Napier D, He S, Liu C, Liu Z, Qian H, Chen L, Wei X, Zheng X, Huang JA, Thibault O, Craven R, Wei D*, Pan Y*, Zhou BP*, Wu Y*, Yang XH*. BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathways. Cell Oncol (Dordr). 2020 Dec;43(6):1049-1066.
5. Yin W#, Ke W, Lu N, Wang Y, Japir AAMM, Mohammed F, Wang Y, Pan Y*, Ge Z*. Glutathione and Reactive Oxygen Species Dual-Responsive Block Copolymer Prodrugs for Boosting Tumor Site-Specific Drug Release and Enhanced Antitumor Efficacy[J].Biomacromolecules.2020 Feb 10;21(2):921-929.
6. Jin W#, Shan B, Liu H, Zhou S, Li W, Pan J, Lin L, Hu D, Pan Y*. Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping. Journal of Thoracic Oncology[J]. 2019 Jul;14(7):e137-e139.
7. Wei Wang*, Wei-Dong Jia, Bing Hu, Yue-Yin Pan*. RAB10 overexpression promotes tumor growth and indicates poor prognosis of hepatocellular carcinoma .Oncotarget 2017 (16) : 26434-26447
8. Yitao Wan#, Yuan Yuan, Yueyin Pan*, Ying Zhang*. Antitumor activity of high-dose pulsatile gefitinib in non-small-cell lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Experimental and Therapeutic Medicine 2017 (6): 3067-3074
Contact Information
E-mail: panyueyin@ustc.edu.cn
Phone: 13805695536